Publication: 2228

Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance)
      QxMD      Google Scholar   
Citation:
Target Oncol vol 12 (2) 201-209
Year:
2017
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
6
Parents:
587  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA035267, N01 CA035431, U10 CA180821, U10 CA035448, U10 CA063848, U10 CA180790, P30 CA015083, U10 CA180882, U10 CA035431, U10 CA025224  
Corr. Author:
 
Authors:
                   
Networks:
HAWAII, LAPS-MN026, METROMIN   
Study
NCCTG-N0745
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
1/2
Keywords:
Article